AnalystsInsight

Douglas Loe (Leede Financial): Analyst Track Record and Price‑Target Accuracy

How often Douglas Loe’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 36 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

Key takeaways

  • Douglas Loe ranks #749 of 1,000 analysts in Exent’s scoring (4.7★).
  • 6.7% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 8 days; 62.5% of calls were up 12 months later.
  • Most‑covered stocks: ONCY, OTC-NEPTF, TSX-CPH, TSX-EXE.
  • Free on Exent: Douglas Loe’s full record, with ratings 3 days after publication.

Douglas Loe’s track record at a glance

Douglas Loe of Leede Financial ranks #749 of the 1,000 analysts Exent scores, with a 4.7★ rating and a focus on healthcare. Over a 7‑year lookback, 6.7% of Douglas’s price targets were reached, 45.7 points below the 52.4% average across all analysts.

MetricDouglas LoeAll analysts
Price‑target hit rate6.7%52.4%
Median days to hit target8 days91 days
Calls up after 12 months62.5%64.0%
Median 12‑month return of calls+16.3%+13.4%
Hit rate, last 2 years0.0%—
Average worst drop after a call−40.3%—
Ratings in the sample36—
Stocks covered19—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetDouglas Loe
Under 30 days100.0%
30–90 days0.0%
90–180 days0.0%
Over 180 days0.0%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Douglas Loe covers most

StockRatings in the sample
ONCY52
OTC-NEPTF36
TSX-CPH35
TSX-EXE34
OTC-IMVIF34
TSX-CRRX33
GRCE31
TSX-SVA26

In the past year Douglas’s ratings were 100% Buy, 0% Hold and 0% Sell.

Douglas Loe’s latest ratings

DateStockActionRatingPrice target
Mar 11, 2026TSX-MSCLReiterated: BuyBuy$22.63
Mar 11, 2026TSX-MSCLMaintainedBuy$22.29
Mar 11, 2026TSX-MSCLMaintained: BuyBuy$22.64
Mar 8, 2026TSXV-PINKReiterated: BuyBuy$3.00
Mar 8, 2026TSXV-PINKReiteratedBuy$3.00
Feb 11, 2026TSX-MSCLReiterated: BuyBuy$22.64
Feb 11, 2026TSX-MSCLReiteratedBuy$22.29
Jan 29, 2026TSX-MSCLInitiated CoverageBuy$37.62
Jan 29, 2026TSX-MSCLInitiated Coverage: BuyBuy$38.21
Nov 27, 2025TSXV-NSCIMaintainedBuy$0.50
Nov 27, 2025TSXV-NSCIReiterated: BuyBuy$0.50
Nov 27, 2025TSXV-NSCIMaintained: BuyBuy$0.50
  • Mar 11, 2026
    Stock
    TSX-MSCL
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $22.63
  • Mar 11, 2026
    Stock
    TSX-MSCL
    Action
    Maintained
    Rating
    Buy
    Price target
    $22.29
  • Mar 11, 2026
    Stock
    TSX-MSCL
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $22.64
  • Mar 8, 2026
    Stock
    TSXV-PINK
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $3.00
  • Mar 8, 2026
    Stock
    TSXV-PINK
    Action
    Reiterated
    Rating
    Buy
    Price target
    $3.00
  • Feb 11, 2026
    Stock
    TSX-MSCL
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $22.64
  • Feb 11, 2026
    Stock
    TSX-MSCL
    Action
    Reiterated
    Rating
    Buy
    Price target
    $22.29
  • Jan 29, 2026
    Stock
    TSX-MSCL
    Action
    Initiated Coverage
    Rating
    Buy
    Price target
    $37.62
  • Jan 29, 2026
    Stock
    TSX-MSCL
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $38.21
  • Nov 27, 2025
    Stock
    TSXV-NSCI
    Action
    Maintained
    Rating
    Buy
    Price target
    $0.50
  • Nov 27, 2025
    Stock
    TSXV-NSCI
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.50
  • Nov 27, 2025
    Stock
    TSXV-NSCI
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $0.50

Douglas’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Douglas Loe’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Douglas Loe ranks #749 of 1,000 with a 4.7★ rating. 6.7% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 62.5% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Douglas Loe’s success rate is 47.0% by the ranking source and 6.7% by Exent’s price-target hit-rate backtest, with a median of 8 days to reach a target.

Douglas Loe (Leede Financial) covers 19 stocks, mostly in healthcare. The most frequently rated are ONCY, OTC-NEPTF, TSX-CPH, TSX-EXE, OTC-IMVIF.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.